Asterias Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing cell-based therapeutics to treat neurological conditions associated with demyelination, and cellular immunotherapies to treat cancer. Its clinical stage programs include AST-OPC1, an oligodendrocyte progenitor cell population derived from pluripotent stem cells that is in Phase I/IIa clinical trial for spinal cord injuries; AST-VAC2 is a non-patient-specific cancer immunotherapy derived from pluripotent stem cells for the treatment of non-small cell lung cancer; and AST-VAC1, a patient-specific cancer immunotherapy that has completed Phase II clinical trial for the treatment of acute myeloid leukemia.
Read More…
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+1-510-4563805
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableOptionable
Asterias Biotherapeutics (NYSEAMERICAN:AST) Frequently Asked Questions
What is Asterias Biotherapeutics' stock symbol?
Asterias Biotherapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "AST."
How were Asterias Biotherapeutics' earnings last quarter?
Asterias Biotherapeutics Inc (NYSEAMERICAN:AST) released its quarterly earnings results on Tuesday, March, 28th. The biotechnology company reported ($0.18) earnings per share for the quarter, missing analysts' consensus estimates of ($0.17) by $0.01. The biotechnology company had revenue of $1.75 million for the quarter, compared to the consensus estimate of $2.81 million. View Asterias Biotherapeutics' Earnings History.
Has Asterias Biotherapeutics been receiving favorable news coverage?
News stories about AST stock have been trending very negative on Monday, according to InfoTrie Sentiment. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Asterias Biotherapeutics earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for Asterias Biotherapeutics.
Who are some of Asterias Biotherapeutics' key competitors?
Some companies that are related to Asterias Biotherapeutics include MorphoSys (MOR), BTG (BTG), MorphoSys (MOR), Cronos Group (CRON), Abcam (ABC), Genus (GNS), Polynovo (PNV), Clinuvel Pharmaceuticals (CUV), Vir Biotechnology (VIR), Concordia International (CXR), Kodiak Sciences (KOD), Immutep (IMM), Mesoblast (MSB), Paradigm Biopharmaceuticals (PAR) and Starpharma (SPL).
What other stocks do shareholders of Asterias Biotherapeutics own?
Who are Asterias Biotherapeutics' key executives?
Asterias Biotherapeutics' management team includes the folowing people:
- Mr. Michael H. Mulroy, CEO, Pres & Director (Age 53)
- Dr. Edward D. Wirth III, Chief Medical Officer (Age 54)
- Dr. Katharine E. Spink, Consultant (Age 45)
- Mr. Stephen L. Cartt, Advisor & Director (Age 56)
- Mr. Ryan D. Chavez, CFO & Gen. Counsel (Age 43)
How do I buy shares of Asterias Biotherapeutics?
Shares of AST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
How big of a company is Asterias Biotherapeutics?
What is Asterias Biotherapeutics' official website?
How can I contact Asterias Biotherapeutics?
Asterias Biotherapeutics' mailing address is 6300 Dumbarton Cir, FREMONT, CA 94555-3644, United States. The biotechnology company can be reached via phone at +1-510-4563805.
MarketBeat Community Rating for Asterias Biotherapeutics (NYSEAMERICAN AST)
MarketBeat's community ratings are surveys of what our community members think about Asterias Biotherapeutics and other stocks. Vote "Outperform" if you believe AST will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AST will underperform the S&P 500 over the long term. You may vote once every thirty days.
